Kraig Biocraft Laboratories has announced the acceleration of its 2024 production schedule, with the successful launch of its BAM-1 recombinant spider silk hybrids. Originally slated for July, the company's production trials surpassed expectations, allowing for an early rollout.

This production phase marks a significant step towards commercializing sustainable and cost-effective spider silk production. It represents a tenfold increase over previous trials and marks the largest single batch of spider silk production in the company's history.

The BAM-1 hybrids, a result of integrating the company's Dragon Silk technology into two robust commercial silkworm strains, exhibited excellent hatching yield and uniform growth. They yield larger cocoons and stronger silkworms, enhancing silk production efficiency while maintaining fiber performance.

Kim Thompson, Founder and CEO of Kraig Labs, expressed pride in the team's efforts, noting over a year of focused development behind the success. With this milestone, the company is on track to achieve its target of producing a metric ton of spider silk.

Further updates on production progress and market developments are expected in the coming weeks.